FGFR3 and urinary bladder cancer: FGFR3 SVs/REs were most frequent in bladder cancer (SVs: 1051/7739, 13.6%; REs: 207/7739, 2.7%) and urinary tract cancer (SVs: 116/850, 13.7%; REs: 19/850, 2.2%; Figure 2C).